BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease

Pulmonary Disease, Chronic Obstructive Clinical Trial

— BREATHE-ALD  

Official title:

The Development and Pilot Testing of a Brief Shared Decision-Making Intervention to Improve Palliative Care Outcomes for Adults With Advanced Lung Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04930666
• Other study ID #: AAAT2217
• Secondary ID: P20NR018072
• Status: Recruiting
• Start date: November 10, 2021
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: Columbia University
• Contact: Maureen George, PhD
• Phone: 2123051175
• Email: mg3656[@]cumc.columbia.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to: 1. Develop the BREATHE-ALD intervention for adults with Advanced Lung Disease, multiple chronic conditions, and palliative care needs and their caregivers using interviews with 10 advanced lung disease (ALD) adults and their caregivers 2. To evaluate the feasibility and acceptability of intervention procedures; and 3. To explore intervention effects on ALD outcomes

Description:

This study addresses the important problem of adults with symptomatic advanced lung disease (ALD) who are at high risk for poor outcomes. Palliative care (PCare) improves the quality of life of individuals and their caregivers through the prevention and relief of suffering by identifying, assessing and treating the physical, psychosocial and spiritual problems associated with life-threatening illness. However, pulmonary clinicians rarely refer adults with ALD to PCare because of time demands, a lack of confidence in PCare and the perceived threat PCare poses to the relationship they have established with the ALD adult. Therefore, we are developing BREATHE-ALD (BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease [ALD]), a novel shared decision-making (SDM) intervention to improve outcomes for adults with ALD. The study includes two phases: (1) a development phase to develop BREATHE-ALD using interviews with 10 ALD adults and their caregivers with expert review to adapt BREATHE, and (2) a pilot validation phase conducting a pilot trial in which 10 adults with ALD receive BREATHE-ALD. We will follow adults with ALD for 3 months post-intervention to assess the impact of BREATHE-ALD on self-management and patient outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Pre-trial

Inclusion Criteria:

• Patient participants with symptomatic advanced lung disease (ALD) followed at Weill Cornell Medicine (WCM).
• Caregiver participants who care for adults with symptomatic ALD followed at Weill Cornell Medicine.

Exclusion Criteria:

• Patients that have serious mental health conditions that preclude completion of study procedures or confound analyses.
• Caregivers that have serious mental health conditions that preclude completion of study procedures or confound analyses. Trial

Inclusion Criteria:

• Patient participants with symptomatic advanced lung disease (ALD) followed at Weill Cornell Medicine (WCM).
• Nurse practitioner must manage a panel of adult ALD patients.

Exclusion Criteria:

• Patients that have serious mental health conditions that preclude completion of study procedures or confound analyses.
• Patients anticipated to have less than 3-month survival.

Related Conditions & MeSH terms

• Lung Diseases
• Lung Diseases, Interstitial
• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease
BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).

Locations

Country	Name	City	State
United States	Weill Cornell Medical Center	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
Columbia University	National Institute of Nursing Research (NINR), Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of qualitative interviews completed in the development phase	Qualitative interviews will be conducted with adults with advanced lung disease and their caregivers to understand their experiences managing ALD using semi-structured in-depth individual interviews. The information collected will aid the design of BREATHE-ALD and the implementation of the pilot phase of this study.	Up to 6 months
Primary	Ratio of participants who completed the intervention to the number of participants consented	To determine the level of retention, the ratio of participants who completed the intervention to the number of participants consented will be measured.	Up to 3 months post-intervention
Primary	Mean mMRC (Modified Medical Research Council) Dyspnea Scale	The mMRC (Modified Medical Research Council) Dyspnea Scale measures the effect of breathlessness when performing daily activities. The mMRC breathlessness scale comprises ?ve statements that describe almost the entire range of respiratory disability from none (Grade 1) to almost complete incapacity (Grade 5).	Up to 3 months post-intervention
Secondary	Mean St. George's Respiratory Questionnaire	The St. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. It is a 50-item questionnaire with two parts, in which part one measures frequency and severity of symptoms while part two measures activities that impact breathlessness. Scores range from 0 to 100, with higher scores indicating more limitations.	Baseline, 1 month, 2 months, and 3 months (post-intervention)
Secondary	Mean PROMIS Pain Intensity - Short Form V10 3a	PROMIS Pain Intensity instrument measures how much a person hurts. It is a 3-item instrument that evaluates how much pain the patient has felt in the past seven days. Each question about pain intensity is rated on a five-point scale from had no pain (1) to very severe (5).	Baseline, 1 month, 2 months, and 3 months (post-intervention)
Secondary	Mean PROMIS Fatigue - Short Form 6a	PROMIS Fatigue instrument measures how much a person feels tired. It is a 6-10-item questionnaire that evaluates how tired or exhausted the patient has felt in the past seven days. Each question about fatigue is rated on a five-point scale from never (1) to always (5).	Baseline, 1 month, 2 months, and 3 months (post-intervention)
Secondary	Mean Short Form 36	Short Form 36 (SF-36) is a well validated instrument that measures overall health status. It consists of 36 items and has eight sections.; the scores are weighted sums of the questions in each section. Scores range from 0-100. Lower scores = more disability and higher scores = less disability	Baseline, 1 month, 2 months, and 3 months (post-intervention)
Secondary	Mean Shared Decision Making Questionnaire	The Shared Decision Making (SDM) Questionnaire-9, is a patient reported, 9-item validated instrument that consists of nine statements that measure the decisional process in medical visits from both patients' and physicians' perspectives. Each statement is rated on a six-point scale from "completely disagree" to "completely agree".	Baseline (immediately post-intervention)